Barclays Maintains an 'Equalweight' on Express Scripts (ESRX), Raises PT
More News related to ESRX
- Stifel Nicolaus Initiates Coverage on Express Scripts (ESRX) with a Hold
- UBS Starts Numerous Healthcare Stocks: CAH, MCK, ESRX at Buy, PMC, OCR at Neutral
- InvestorSoup.com issues Technical Trading Outlook for Health Sciences Group Inc.
- Griffin's Blue Ridge Likes A Major Bank, Swaps Into Gold Miner ETF, Picks Up More Silver and Makes Moves In Tech
- Express Scripts to Build High Volume Filler Pharmacy in St. Louis
More News related to Analyst Comments
- Auriga Reiterates a 'Buy' on McDermott International (MDR); Upstream/Government Story Trumps Quarterly Noise
- Citi Upgrades Chile Stocks to Overweight, Downgrades Colombia Stocks to Neutral
- Baird Maintains a 'Neutral' Rating on Cephalon (CEPH), Reslizumab Mixed Results in EE Sets Back Potential for Upside
- Wedbush Removes McDonald's (MCD) from 'Best Ideas' List; Reiterates Outperform
- Piper Jaffray Maintains an 'Overweight' on Cephalon (CEPH); Buy on Weakness
Barclays maintains an Equalweight on Express Scripts (Nasdaq: ESRX), raises PT to $95 from $92.
To see more analyst ratings on ESRX Click Here.
Express Scripts, Inc. offers a range of pharmacy benefit management (PBM) services in North America.
Related Categories
Analyst CommentsStocks Mentioned
+2.86Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
